Eftilagimod alpha, a first-in-class soluble LAG-3 protein which acts as MHC class II agonist, has recently shown an overall response rate (ORR) of 55% and a disease control rate of 87.5% in combination with anti-PD-1 and chemotherapy in advanced NSCLC (phase I INSIGHT-003 trial [NCT03252938]) [37]. Here, PDCD1 is linked to non-small cell lung carcinoma.